Literature DB >> 11547901

Muc4/sialomucin complex in the mammary gland and breast cancer.

K L Carraway1, S A Price-Schiavi, M Komatsu, S Jepson, A Perez, C A Carraway.   

Abstract

MUC4 is a one of the membrane mucins of the mucin gene (MUC) family, characterized by mucin tandem repeat domains and a transmembrane domain which associates it with the cell plasma membrane. Although MUC4 is encoded by a single gene, it is produced by epithelial cells as a heterodimer through a proteolytic cleavage mechanism. This heterodimer is found in both membrane and soluble forms associated with epithelia. Functionally, MUC4 is proposed to provide a protective mechanism for vulnerable epithelia, such as those of the airway, eye, female reproductive tract and mammary gland. The protective mechanism(s) may be highjacked by some carcinomas, such as those of the breast, to increase tumor progression. Two mechanisms are proposed to contribute to the MUC4 functions. First, MUC4 acts as an anti-adhesive or anti-recognition barrier at epithelial or tumor cell surfaces. Second, MUC4 can bind the receptor tyrosine kinase ErbB2 and alter its cellular signaling. Expression of MUC4 in mammary gland is repressed by posttranscriptional mechanisms involving basement membrane and TGF-beta, which are relieved during pregnancy to permit secretion of MUC4 into milk. These mechanisms are also abrogated in some breast cancers, providing a scenario for promotion of tumor progression. These observations imply important functions for MUC4 in both normal mammary function and in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11547901     DOI: 10.1023/a:1011327708973

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  86 in total

Review 1.  Structural cues from the tissue microenvironment are essential determinants of the human mammary epithelial cell phenotype.

Authors:  K L Schmeichel; V M Weaver; M J Bissell
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-04       Impact factor: 2.673

2.  Chemical structure of epiglycanin, the major glycoprotein of the TA3-Ha ascites cell. The carbohydrate chains.

Authors:  D H Van den Eijnden; N A Evans; J F Codington; V Reinhold; C Silber; R W Jeanloz
Journal:  J Biol Chem       Date:  1979-12-10       Impact factor: 5.157

3.  Cell-surface glycoproteins of two sublines of the TA3 tumor.

Authors:  J F Codington; B H Sanford; R W Jeanloz
Journal:  J Natl Cancer Inst       Date:  1973-08       Impact factor: 13.506

4.  Sialomucin complex, a heterodimeric glycoprotein complex. Expression as a soluble, secretable form in lactating mammary gland and colon.

Authors:  E A Rossi; R R McNeer; S A Price-Schiavi; J M Van den Brande; M Komatsu; J F Thompson; C A Carraway; N L Fregien; K L Carraway
Journal:  J Biol Chem       Date:  1996-12-27       Impact factor: 5.157

5.  Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells.

Authors:  K O Lloyd; J Burchell; V Kudryashov; B W Yin; J Taylor-Papadimitriou
Journal:  J Biol Chem       Date:  1996-12-27       Impact factor: 5.157

6.  Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells.

Authors:  J J Oh; D R Grosshans; S G Wong; D J Slamon
Journal:  Nucleic Acids Res       Date:  1999-10-15       Impact factor: 16.971

7.  Expression and localization of immunoreactive-sialomucin complex (Muc4) in salivary glands.

Authors:  P Li; M E Arango; R E Perez; C A Reis; E L Bonfante; D Weed; K L Carraway
Journal:  Tissue Cell       Date:  2001-02       Impact factor: 2.466

8.  High-Mr glycoprotein profiles in human milk serum and fat-globule membrane.

Authors:  M Shimizu; K Yamauchi; Y Miyauchi; T Sakurai; K Tokugawa; R A McIlhinney
Journal:  Biochem J       Date:  1986-02-01       Impact factor: 3.857

Review 9.  Tumor sialomucin complexes as tumor antigens and modulators of cellular interactions and proliferation.

Authors:  K L Carraway; N Fregien; K L Carraway; C A Carraway
Journal:  J Cell Sci       Date:  1992-10       Impact factor: 5.285

10.  Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components.

Authors:  J Wesseling; S W van der Valk; H L Vos; A Sonnenberg; J Hilkens
Journal:  J Cell Biol       Date:  1995-04       Impact factor: 10.539

View more
  34 in total

Review 1.  Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy.

Authors:  Partha Mukhopadhyay; Subhankar Chakraborty; Moorthy P Ponnusamy; Imayavaramban Lakshmanan; Maneesh Jain; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2011-01-26

2.  A signaling mucin at the head of the Cdc42- and MAPK-dependent filamentous growth pathway in yeast.

Authors:  Paul J Cullen; Walid Sabbagh; Ellie Graham; Molly M Irick; Erin K van Olden; Cassandra Neal; Jeffrey Delrow; Lee Bardwell; George F Sprague
Journal:  Genes Dev       Date:  2004-07-15       Impact factor: 11.361

Review 3.  A perspective of comparative salivary and breast pathology. Part I: microstructural aspects, adaptations and cellular events.

Authors:  Asterios Triantafyllou; Jennifer L Hunt; Kenneth O Devaney; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-05-07       Impact factor: 2.503

Review 4.  Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Marina Paini; Stefano Crippa; Stefano Partelli; Filippo Scopelliti; Domenico Tamburrino; Andrea Baldoni; Massimo Falconi
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

5.  Resistance to trastuzumab in HER2-positive mucinous invasive ductal breast carcinoma.

Authors:  Zora Baretta; Rodrigo Santa Cruz Guindalini; Galina Khramtsova; Olufunmilayo I Olopade
Journal:  Clin Breast Cancer       Date:  2012-12-29       Impact factor: 3.225

6.  Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [(89)Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model.

Authors:  Zéna Wimana; G Gebhart; T Guiot; B Vanderlinden; R Morandini; G Doumont; F Sherer; G Van Simaeys; S Goldman; G Ghanem; P Flamen
Journal:  Mol Imaging Biol       Date:  2015-10       Impact factor: 3.488

7.  Resistance to Trastuzumab in Breast Cancer.

Authors:  Paula R Pohlmann; Ingrid A Mayer; Ray Mernaugh
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

8.  Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.

Authors:  M F E Godinho; A M Sieuwerts; M P Look; D Meijer; J A Foekens; L C J Dorssers; T van Agthoven
Journal:  Br J Cancer       Date:  2010-09-21       Impact factor: 7.640

Review 9.  Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.

Authors:  Charles Vogel; Arlene Chan; Brunilde Gril; Sung-Bae Kim; Junichi Kurebayashi; Li Liu; Yen-Shen Lu; Hanlim Moon
Journal:  Jpn J Clin Oncol       Date:  2010-06-11       Impact factor: 3.019

Review 10.  Review of the adenocarcinoma cell surface receptor for human alpha-fetoprotein; proposed identification of a widespread mucin as the tumor cell receptor.

Authors:  G J Mizejewski
Journal:  Tumour Biol       Date:  2013-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.